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Abstract
Background: To report acute toxicity, initial outcome results and planning therapeutic parameters in radiation
treatment of advanced lung cancer (stage III) with volumetric modulated arcs using RapidArc (RA).
Methods: Twenty-four consecutive patients were treated with RA. All showed locally advanced non-small cell lung
cancer with stage IIIA-IIIB and with large volumes (GTV:299 ± 175 cm
3, PTV:818 ± 206 cm
3). Dose prescription was
66Gy in 33 fractions to mean PTV. Delivery was performed with two partial arcs with a 6 MV photon beam.
Results: From a dosimetric point of view, RA allowed us to respect most planning objectives on target volumes
and organs at risk. In particular: for GTV D1% = 105.6 ± 1.7%, D99% = 96.7 ± 1.8%, D5%-D95% = 6.3 ± 1.4%; contra-
lateral lung mean dose resulted in 13.7 ± 3.9Gy, for spinal cord D1% = 39.5 ± 4.0Gy, for heart V45Gy = 9.0 ± 7.0Gy,
for esophagus D1% = 67.4 ± 2.2Gy. Delivery time was 133 ± 7s. At three months partial remission > 50% was
observed in 56% of patients. Acute toxicities at 3 months showed 91% with grade 1 and 9% with grade 2
esophageal toxicity; 18% presented grade 1 and 9% with grade 2 pneumonia; no grade 3 acute toxicity was
observed. The short follow-up does not allow assessment of local control and progression free survival.
Conclusions: RA proved to be a safe and advantageous treatment modality for NSCLC with large volumes. Long
term observation of patients is needed to assess outcome and late toxicity.
Background
Lung cancer remains the major cause of cancer-related
mortality worldwide. Non-small cell lung cancer
(NSCLC) account for at least 80% of all lung tumors
and about 30% of them present with unresectable locally
advanced disease at diagnosis (stage IIIA-IIIB) [1]. Until
the mid 1980s standard treatment of patients with inop-
erable locally advanced NSCLC consisted of radiother-
apy (RT) alone with a median survival time of 10
months[1]. From data about lung cancer population
diagnosed in the second half of 1990s, overall survival at
one and two years was estimated of 36% and 12%
respectively[2].
Rates at 2 and 5 years of 15% and 5% respectively [3].
In attempts to improve the survival in these patients,
chemotherapy was added to external beam irradiation.
Several trials have been positive in favour of combined
therapy [4-6]. More recently, other clinical trials have
shown that, in selected patients (good performance sta-
tus, age ≤ 75 years and minimal weight loss) concomi-
tant platinum-based chemo-radiotherapy is feasible with
improvement in progression-free survival and overall
survival (OS) in comparison with sequential chemo-
radiotherapy (OS 4 years 21% vs. 14%) [7]. However,
survival for patients with unresectable locally advanced
NSCLC is extremely poor with high rates of loco-
regional failure. Recent trials suggest that dose escala-
tion RT could improve loco-regional control with likely
b e n e f i to no v e r a l ls u r v i v a l[ 8 - 1 0 ] .R e n g a ne ta lr e v i e w e d
the treatment of stage III tumors with large gross tumor
volumes (GTV) using 3D-CRT, founding 10 Gy increase
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failure rates [9]. Unfortunately, the large volume of
tumor makes dose escalation difficult when using 3D-
CRT, since, to avoid treatment related complications
such as severe pneumonitis, it is necessary to keep the
mean lung dose (MLD) below 20Gy approximately [11].
More recently, the development of intensity modu-
lated radiotherapy (IMRT) makes it possible to deliver a
high therapeutic effective dose to the target volume with
maximum preservation of surrounding normal tissues.
Many studies have compared IMRT and 3D-CRT plans
for patients with large unresectable locally advanced
NSCLC. Results show statistically significant differences
in V20, V30 and MLD for contralateral lung with the
values in the IMRT plans being lower. The benefits
seemed most pronounced in medium to large tumours
[12].
A recent retrospective clinical trial of MSKCC
reported a 2-year local control and overall survival of
58% and 58% respectively and a median survival time of
25 months for patients with inoperable stage III lung
cancer and treated with 70 Gy (range 60-90 Gy) using
IMRT [13]. The results of this study suggest that dose
escalation could have an effect not only on local control
but also on survival.
To implement dose escalation strategy on NSCLC,
advanced IMRT delivery technologies such as Helical
Tomotherapy were used and compared with three-
dimensional conformal radiotherapy in the clinical prac-
tice[14,15]. Both Helical Tomotherapy, and to a lesser
extent conventional three-dimensional conformal radio-
therapy, have shown the potential to significantly
decrease radiation dose to lung and other normal struc-
tures in the treatment of NSCLC, providing important
implications, in terms of acceptable acute toxicities
recorded, for dose escalation strategies in the future
[15,16]. In a report of volumetric changes, measured in
the primary tumor on megavoltage-computed tomogra-
phy (MVCT) during chemoradiation, Helical Tomother-
a p ys h o w e da l s ot ob ee f f e c t i v ei nr e d u c et u m o u r
volume in NSCLC[17].
RapidArc(RA), a volumetric modulated arc therapy
based on the original investigation of K. Otto [18], has
been recently introduced in clinical practice in several
institutes after an intensive validation at planning level,
compared to IMRT or other approaches, in a series of
studies including brain tumours, prostate, head and
neck, mesothelioma, cervix uteri and other indications
[19-25].
RA is implemented as the Progressive Resolution
Optimisation (PRO) algorithm in the Eclipse planning
system by Varian Medical System (Palo Alto, California,
USA). The optimisation process is based on an iterative
inverse planning process that aims to simultaneously
optimise the instantaneous multi-leaf collimator (MLC)
positions, the dose rate, and the gantry rotation speed in
order to achieve the desired dose distribution.
In this study, our aim was to investigate the potential
of RA to deliver a therapeutic dose to large volume
unresectable NSCLC. We also investigated the possibi-
lity of sparing lung tissue, esophagus, heart and spinal
cord using RA with the aim of paving the way for
further study of dose escalation In the present study,
acute toxicities and initial outcome results, were evalu-
ated and reported.
Methods
Patients and procedures
This study includes patients with large volume unresect-
able locally advanced NSCLC (Stage IIIA-IIIB). From
May 2009 to September 2009, 24 patients referred to
our institution for NSCLC underwent volumetric modu-
lated arc therapy by RA technique. Of these patients 19
were men and 5 women, with a median age of 67 years
(range 43-84 years). The total volume of CTV and PTV
were recorded for all patients. Specific patients’ charac-
teristics are reported in table 1.
The patient’s general conditions (age, performance sta-
tus, weight loss and co-morbidity) were recorded. Total
body computed tomography (CT) scan, FDG positron
emission tomography (PET) and bone scans were per-
formed in each patient before treatment. In the present
population of study, FDG PET was not performed in
treatment position and PET images were used by clini-
cian only to obtain a complete stadiation of the patients
Table 1 Summary of patients characteristics at treatment
start. Values are expressed in number of patients when
not otherwise specified
Number of patients 24
Sex Males 19
Females 5
Age [years]
(median and range)
67 y (43-84)
Histology Adenocarcinoma 12
Squamous 7
NSCLC NAS 5
Stage IIIA 11
IIB 13
Treatment Sequential 8
Concurrent
Chemotherapy
11
RT alone 5
Radiation Dose
Prescription
66 Gy/33fractions 22
60 Gy/30fractions 1
50 Gy/25fractions 1
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Page 2 of 9before treatment. Pathological diagnosis was made by
CT-guided fine needle biopsy in 8 patients; 6 patients
underwent mediastinoscopy; 4 patients underwent thor-
acotomy and 6 patients underwent bronchoscopy.
Sequential or concomitant chemotherapy was performed
in patients of one or more of the following: i) age ≤ 75
years, ii) PS 0-1, iii) minimum weight loss (< 10%
6 months before diagnoses) and iv) Absence of impor-
tant co-morbidity. Radiotherapy alone was prescribed in
patients of one or more of the following:.i) age
≥75 years, ii) PS 1-2, iii) minimum weight loss (> 10%
6 months before diagnoses.
All patients received a planning CT scan and were
immobilized in a supine position within a personal body-
fix pillow. During the scan, and the treatment, patients
breathed freely, with the indication to maintain a breath-
ing cycle as regular as possible. The Gross Tumor
Volume (GTV) consisted of all known sites of disease
with no elective nodal targets. The GTV was defined
“large” if it was ≥ 100 cc. The PTV was defined applying
an isotropic margin of 8 mm from the primary tumor
and of 5 mm from the involved regional lymph nodes.
The protocol of treatment started with patients present-
ing stage III lung cancer in the upper quadrant, and with
target volume: > 400 cm
3. According to Liu et al. [26] the
motion of these lesions is lower than 3 mm, therefore the
use of 4D techniques is unnecessary. Furthermore daily
kV-cone beam CT (CBCT) is performed before RT treat-
ment in order to verify the correct patient position and
the target motion (considering the CBCT as a slow CT
that includes the lesion motion). Despite daily image
guided have already shown in lung the advantage to
quantify the volumetric tumour response during treat-
ment [17], in the present study CBCTs were utilized only
for patient daily set-up correction.
Organs at risk routinely considered in these patients
are contra- and ipsi-lateral lungs, heart, spinal cord and
oesophagus. In addition, for all intensity modulated
patients, the Healthy Tissue (HT) was defined as the
patient’s volume included in the CT dataset minus the
PTV volume. Volumes are reported in tables 2 and 3.
All patients were treated with conventional fractiona-
tion (2 Gy/day) with no planned treatment breaks. Total
dose prescription was 66Gy/33 fractions (with the
exception of two patients, one receiving 50Gy and one
60Gy due to OARs limiting factors). In all cases dose
normalization was set to mean dose to PTV.
Plans were optimized for two partial isocentric arcs
for a Clinac 2100 equipped with a Millennium-120
MLC (120 leaves with a resolution at isocentre of 5 mm
f o rt h ei n n e r2 0c ma n d1 0m mf o rt h eo u t e r2×1 0
cm) and a beam energy of 6MV. The arc lengths were
set in order to avoid entrance from the contra-lateral
lung (depending on target location and extension), and
to avoid the posterior entrances, where the couch bars
were positioned. For further details on the RapidArc
technique see references [15,16].
Plan optimization was performed requiring PTV cov-
erage of 95%-107%. With regard to OARs, the primary
objectives were: Spinal cord: D1% < 46Gy; Contra lateral
lung: V20Gy < 30%, mean dose < 15Gy; Oesophagus: D1%
< 70 Gy. Secondary objectives: Ipsilateral lung: V20Gy as
low as possible
Oesophagus: V55Gy <3 0 % ;H e a r t :V 50Gy <2 0 % ,V 45Gy
< 30%.
Table 2 Summary of DVH analysis for CTV and PTV
Objective RA
CTV
(mean+1SD)
PTV
(mean+1SD)
Volume [cm
3] 299 ± 175 818 ± 206
Mean [%] 100 101.0 ± 1.2 100.0 ± 0.0
D1% [%] < 107% 105.6 ± 1.7 105.6 ± 1.6
D5-95% [%] Minimize 6.3 ± 1.4 9.1 ± 1.3
D99% [%] > 95% 96.7 ± 1.8 91.6 ± 2.2
V95% [%] 100 99.6 ± 0.6 94.6 ± 4.1
V107% [%] 0 0.7 ± 1.3 0.7 ± 1.7
Table 3 Summary of DVH analysis for organs at risk
Objective RA
Ipsi-lateral lung
Volume [cm
3] - 1717 ± 549
Mean [Gy] Minimize 30.4 ± 7.0
V20Gy [%] Minimize 52.8 ± 8.9
Contra-lateral lung
Volume [cm
3] - 1945 ± 517
Mean [Gy] < 15 Gy 13.7 ± 3.9
V20Gy [%] < 20-30% 21.1 ± 6.1
Spinal Cord
Volume [cm
3] -3 9 ± 1 6
D1% [Gy] < 45 Gy 39.5 ± 4.0
Heart
Volume [cm
3] - 715 ± 161
V45Gy [%] < 30% 9.0 ± 7.0
V50Gy [%] < 20% 6.9 ± 6.3
Esophagus
Volume [cm
3] -3 7 ± 1 3
V55Gy [%] < 30% 33.3 ± 10.0
D1% [Gy] < 70 Gy 67.4 ± 2.2
Healthy tissue
Volume [cm
3] - 29588 ± 7788
Mean [Gy] - 9.5 ± 2.7
V10Gy [%] - 27.6 ± 7.7
Dx% = dose received by the x% of the volume; Vx% = volume receiving at
least x% of the prescribed dose; CI = ratio between the patient volume
receiving at least 95% of the prescribed dose and the volume of the total
PTV. DoseInt = Integral dose, [Gy cm
3 10
5].
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Page 3 of 9If the primary objectives were not fulfilled, the pre-
scribed dose was reduced. One patient received 60Gy
and another only 50Gy due to organs at risk dose limit-
ing factors.
All dose distributions were computed with the Analy-
tical Anisotropic Algorithm (AAA, version 8.6) imple-
mented in the Eclipse planning system with a
calculation grid resolution of 2.5 mm.
Outcome evaluation
All patients were evaluated weekly with physical and
hematologic examination during radiation treatment.
Acute and late toxicity events were scored according to
the radiation therapy oncology group (RTOG) and the
European organization for research and treatment of
cancer (EORTC) criteria [27]. Acute reactions included
those occurred during or within the first 4 months after
the start of radiation treatment and late complications
those occurred or persisted after 4 months.
Evaluation of tumor response was performed 45 days
after the end of treatment and then every 3 months
thereafter with total body CT and/or PET/CT scans.
Tumor response was defined according to the Response
Evaluation Criteria in Solid Tumor (RECIST) [28]. Clini-
cal and radiographic evidence of local or distant tumor
recurrence was recorded.
Data analysis
Technical features of treatments have been reported in
terms of main delivery parameters (number of arcs, con-
trol point size, MU, MU/deg and MU/Gy, Dose Rate,
Gantry speed, Collimator angle, beam-on and treatment
time); beam-on and treatment times are defined without
inclusion of patient positioning and imaging procedures
and were scored from the record and verify electronic
system. Results of pre-treatment plan quality assurance
are reported as Gamma Agreement Index (GAI), i.e. the
percentage of modulated field area passing the g-index
criteria of Low [29] with thresholds on dose difference
set to Δ = 3% of the significant maximum dose, and on
Distance to Agreement set to DTA = 3 mm. Measure-
ments and analysis were performed by means of the
GLAaS methodology described in [30,31] based on
absorbed dose to water from EPID measurements.
Dosimetric quality of the treatments was measured from
dose volume histogram (DVH) analysis. For PTV the fol-
lowing data was reported: target coverage (D1%,D 99%,V 95%,
V107%), homogeneity (D5%-D95%). For OARs, the mean
dose, the maximum dose (D1%) and appropriate values of
VxGy (volume receiving at least × Gy) were scored.
Results
Twenty-four patients with large volume NSCLC were
treated with a median dose of 66 Gy (range:50-66 Gy)
or more using RA from May 2009 to September 2009.
All patients had tumors that were unresectable for site
and stage. Eleven patients were stage IIIB and 13
patients stage IIIA. Eleven selected patients (age < 70
years, minimum weight loss < 10% 6 months before
diagnosis, and PS 0) were treated with concurrent plati-
num-based chemo-radiation therapy. Eight patients were
treated with sequential chemo-radiotherapy, and 5
patients with RT alone because unfit for chemotherapy
or elderly.
Only early results are available regarding clinical out-
comes. As planned, there were no interruptions during
the course of the radiation treatment. No patients had
acute skin toxicity. Esophageal toxicity was mild. No
Grade 3 toxicity occurred. Grade 1 and Grade 2 acute
esophageal toxicity occurred in 22/24 and 2/24 patients
respectively. Persistent cough requiring narcotic and
antitussive agents occurred in 10/24 patients. For sub-
acute toxicity, asymptomatic pneumonia occurred in 6
patients (four grade 1, and two grade 2) who underwent
concurrent chemo-radiotherapy at 45 days from the end
of treatment and regressed with antibiotic therapy, with-
out hospitalization. Compared with exclusive radiother-
apy group, hematologic toxicity was higher in
Chemoradiation one, but there was not acute toxicity >
Grade 3 or interruptions. There wasn’t an important
effect of side effects on weight loss for the population of
study and PS was not significantly reduced during treat-
ment. The median follow-up time was 6 months.
A partial remission > 50% was seen at three months in
56% (14/24) of patients, a partial remission < 50% in
22% (5/24) and stable disease in 22%. No progressive
disease occurred. Figure 1 shows a case of significant
remission (> 75%) at 5 months after completion of
radiotherapy as detected with routing CT scan during
follow-up.
Figure 2 shows examples of dose distributions for one
patient. Colour wash is in the interval from 7 to 71Gy.
GTV, PTV and organs at risk are outlined as solid lines
in the images. Figure 3 reports the average dose volume
histograms for GTV, PTV, organs at risk and healthy
tissue. Lines represent the inter-patient variability at one
standard deviation.
Table 4 summarizes the technical features of the treat-
ment characteristics. Results of the DVH analysis are
reported in Table 2 for PTV and GTV, and in table 3
for organs at risk and healthy tissue, together with the
specific objectives.
Dosimetric data showed that RapidArc obtained the
achievement with respect to planning objectives for
most of the parameters considered. In particular, the
target coverage and dose homogeneity are well achieved,
even in regions with highly demanding heterogeneities
(GTV well within the thresholds of 95% and 107%).
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Page 4 of 9In terms of organs at risk the contralateral lung pre-
sented promising results, while keeping the maximum
significant dose to the spinal cord well below the toler-
ance level. Heart irradiation was not of major concern
for the selected patients due to the relatively cranial tar-
get location. The oesophagus volume irradiated to doses
higher than 55Gy is in average higher than objective by
about 3%, but this value is largely dependent on the
organ volume included inside the target volume. As
expected from an intensity modulation arc technique
the low dose bath is not negligible, showing about 8000
cm
3 of tissue irradiated at 10Gy dose level.
Pre-treatment quality assurances of RA plans resulted
in an average gamma agreement index GAI 3% superior
to the acceptance threshold of 95% set as a reference in
our institute.
Discussion
Despite an improvement in survival the prognosis of
patients with unresectable local advanced NSCLC (stage
IIIA-IIIB) remains poor both for locoregional failure and
for distant metastatic disease. Concurrent chemo-radia-
tion is at present the standard of care. Given that local
recurrence is the leading cause of death in this patient
Figure 1 A case of partial remission. Up: pre-treatment; Center: dose distribution; Down: 6 months after end of the therapy.
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have a positive impact on survival rates and quality of
life. The value of dose escalation was demonstrated in a
study from MSKCC; Rengan et al founded that a 10 Gy
increased in dose correlated to a 36.4% decrease in local
failure rates [9]. Unfortunately, the extension of disease
and the presence of surrounding HT makes it often dif-
ficult to deliver high doses with curative intent.
Based on the results of an intensive program of pre-
clinical investigations performed at planning level
[19-25] for assessing the reliability and potential benefit
of RA, this technique has been used in clinical practice
for a variety of indications at our Institute since Novem-
ber 2008. The present study reports the early findings
from the treatment of a group of 24 patients affected by
advanced lung cancer irradiated with RapidArc.
The main objective in the initial clinical introduction
of RA is the evaluation of the possibility to provide RT
treatments respecting a set of planning objectives. These
results should be achieved without introducing elements
of potential confusion like alterations of the fractiona-
tion schemes (acceleration or hypo-fractionation for
example) or dose escalation [14]. Further studies will
assess the elements of improvement once the safety of
the new approach is consolidated in routine practice.
These results could enable the activation of a second
phase dose trial aiming to push RapidArc towards
improved sparing of organs at risk, particularly the con-
tra-lateral lung.
Having achieved the result of respecting or improving
most of the planning objectives, RapidArc confirmed
also some advantages at a logistical level. It provided a
significant efficiency in dose delivery treatment time,.
This is a particularly important point for patients pre-
senting advanced lung cancer, who might have breathing
difficulties in supine position, or even coughing if lying
for a long time: shortening the time spent on the couch
permits the treatment for this class of patients.
From the clinical point of view, the data presented
here are encouraging, confirming that RA can be con-
sidered as a safe modality for this category of patients
having proved limited impact in terms of acute toxicity
[32,33]. The smoother process of RA and its potential
reduction in acute toxicity could also lead to a more
uniform duration of treatments, reducing the risk of
unscheduled and undue interruptions.
In particular, the authors point out the extension of
disease to be greater than other population finding in
Figure 2 Isodose distributions for one example patient for an axial plane, sagittal and coronal views. Doses are shown in colorwash
within the interval from 7 to 71Gy. GTV, PTV, and organs at risk are outlined as solid lines. Figure legend text.
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Page 6 of 9literature. Sura et al. [13] report mean PTV volume of
459 cm
3, much smaller than our series, where mean
PTV volume was 818 cm
3, thus corroborating our
results.
It is obvious that the present study cannot be consid-
ered as conclusive and that long-term observation of
patients is needed to define outcome and late toxicity.
These preliminary results are encouraging additional
experience in this field. Further investigations will aim
to look at the long term clinical outcome and late toxi-
city as well as improvements in sparing of the organs at
risk.
Conclusions
Twenty-four patients with large volume unresectable
locally advanced lung cancer were treated with RA at
Istituto Clinico Humanitas. Quality of treatments
resulted in a general fulfilment of the planning
Figure 3 Average dose volume histograms for GTV, PTV, organs at risk and healthy tissue. Dashed lines represent inter-patient variability
at 1 standard deviation.
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Page 7 of 9objectives. Clinical outcome for early acute toxicity
showed limited events. Future investigations will aim to
increase sparing of organs at risk and to look to long-
term outcome based on the fact that the first phase has
achieved the primary goal of demonstrating the safety
and efficacy of RA.
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